Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD

Published in peer-reviewed journal Ophthalmology and Therapy Research underpins sozinibercept's potential as novel, first-in-class VEGF-C/D 'trap' to prevent blood vessel growth and vascular leakage in the retina __________________ MELBOURNE, Australia and PRINCETON, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related ma ...